Equities research analysts expect TRACON Pharmaceuticals Inc (NASDAQ:TCON) to report $710,000.00 in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for TRACON Pharmaceuticals’ earnings. The highest sales estimate is $910,000.00 and the lowest is $510,000.00. TRACON Pharmaceuticals posted sales of $620,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 14.5%. The company is expected to report its next quarterly earnings results on Tuesday, February 27th.
On average, analysts expect that TRACON Pharmaceuticals will report full-year sales of $710,000.00 for the current year, with estimates ranging from $9.26 million to $11.00 million. For the next financial year, analysts anticipate that the company will post sales of $26.79 million per share, with estimates ranging from $2.38 million to $45.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover TRACON Pharmaceuticals.
TRACON Pharmaceuticals (NASDAQ:TCON) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.07 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.32. TRACON Pharmaceuticals had a negative net margin of 201.21% and a negative return on equity of 83.43%. The company had revenue of $7.50 million during the quarter, compared to analysts’ expectations of $7.60 million.
Shares of TRACON Pharmaceuticals (TCON) traded down $0.25 during mid-day trading on Friday, reaching $2.80. 891,204 shares of the company’s stock traded hands, compared to its average volume of 169,578. The company has a debt-to-equity ratio of 0.24, a current ratio of 3.80 and a quick ratio of 3.80. TRACON Pharmaceuticals has a 52 week low of $2.00 and a 52 week high of $5.40. The stock has a market cap of $53.41, a PE ratio of -2.30 and a beta of 2.41.
A hedge fund recently bought a new stake in TRACON Pharmaceuticals stock. Candriam Luxembourg S.C.A. acquired a new position in shares of TRACON Pharmaceuticals Inc (NASDAQ:TCON) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 143,000 shares of the biopharmaceutical company’s stock, valued at approximately $450,000. Candriam Luxembourg S.C.A. owned about 0.86% of TRACON Pharmaceuticals at the end of the most recent quarter. 34.06% of the stock is currently owned by hedge funds and other institutional investors.
TRACON Pharmaceuticals Company Profile
TRACON Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.